Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma
Conditions
Sarcoma, Nausea, Vomiting
Trial Timeline
Dec 1, 2006 → Jun 1, 2011
NCT ID
NCT00410488About Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone
Palonosetron - Single Dose + Palonosetron - Triple Dose + Adriamycin + Ifosfamide chemotherapy (AI) + Zinecard + Mesna + Vincristine + Dexamethasone is a pre-clinical stage product being developed by Eisai for Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00410488. Target conditions include Sarcoma, Nausea, Vomiting.
What happened to similar drugs?
1 of 15 similar drugs in Sarcoma were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00410488 | Pre-clinical | Completed |
Competing Products
20 competing products in Sarcoma